China
· Delayed Price · Currency is CNY Shenzhen Hepalink Pharmaceutical Group Statistics
Total Valuation
Shenzhen Hepalink Pharmaceutical Group has a market cap or net worth of CNY 13.60 billion. The enterprise value is 14.91 billion.
| Market Cap | 13.60B |
| Enterprise Value | 14.91B |
Important Dates
The next estimated earnings date is Saturday, March 29, 2025.
| Earnings Date | Mar 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Shenzhen Hepalink Pharmaceutical Group has 1.47 billion shares outstanding. The number of shares has decreased by -0.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.47B |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 2.21% |
| Float | 421.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 19.86 |
| PS Ratio | 2.77 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | 7.14 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 49.60, with an EV/FCF ratio of 7.05.
| EV / Earnings | -101.90 |
| EV / Sales | 2.73 |
| EV / EBITDA | 49.60 |
| EV / EBIT | n/a |
| EV / FCF | 7.05 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.35.
| Current Ratio | 2.39 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 14.34 |
| Debt / FCF | 2.04 |
| Interest Coverage | -0.58 |
Financial Efficiency
Return on equity (ROE) is -1.34% and return on invested capital (ROIC) is -0.34%.
| Return on Equity (ROE) | -1.34% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -0.34% |
| Revenue Per Employee | 2.62M |
| Profits Per Employee | -70,343 |
| Employee Count | 2,080 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.09% in the last 52 weeks. The beta is 0.48, so Shenzhen Hepalink Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -12.09% |
| 50-Day Moving Average | 11.21 |
| 200-Day Moving Average | 10.01 |
| Relative Strength Index (RSI) | 29.98 |
| Average Volume (20 Days) | 4,909,345 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group had revenue of CNY 5.45 billion and -146.31 million in losses. Loss per share was -0.10.
| Revenue | 5.45B |
| Gross Profit | 953.36M |
| Operating Income | -93.68M |
| Pretax Income | -222.31M |
| Net Income | -146.31M |
| EBITDA | 267.21M |
| EBIT | -93.68M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 3.08 billion in cash and 4.31 billion in debt, giving a net cash position of -1.23 billion or -0.84 per share.
| Cash & Cash Equivalents | 3.08B |
| Total Debt | 4.31B |
| Net Cash | -1.23B |
| Net Cash Per Share | -0.84 |
| Equity (Book Value) | 12.21B |
| Book Value Per Share | 8.27 |
| Working Capital | 6.03B |
Cash Flow
In the last 12 months, operating cash flow was 2.42 billion and capital expenditures -310.32 million, giving a free cash flow of 2.11 billion.
| Operating Cash Flow | 2.42B |
| Capital Expenditures | -310.32M |
| Free Cash Flow | 2.11B |
| FCF Per Share | 1.44 |
Margins
Gross margin is 17.49%, with operating and profit margins of -1.72% and -2.68%.
| Gross Margin | 17.49% |
| Operating Margin | -1.72% |
| Pretax Margin | -4.08% |
| Profit Margin | -2.68% |
| EBITDA Margin | 4.90% |
| EBIT Margin | -1.72% |
| FCF Margin | 38.78% |
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
| Earnings Yield | -0.97% |
| FCF Yield | 14.02% |
Stock Splits
The last stock split was on June 13, 2016. It was a forward split with a ratio of 1.6.
| Last Split Date | Jun 13, 2016 |
| Split Type | Forward |
| Split Ratio | 1.6 |
Scores
Shenzhen Hepalink Pharmaceutical Group has an Altman Z-Score of 2.4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.4 |
| Piotroski F-Score | n/a |